ABBV-932 for Healthy Subjects

Overseen By ABBVIE CALL CENTER

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: AbbVie

Disqualifiers: Epilepsy, Cardiac, Respiratory, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 day

28 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, since the trial is for healthy subjects, it's possible that participants should not be on any regular medications.

What is the purpose of this trial?

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Research Team

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This trial is for healthy adults who can safely take the experimental medication ABBV-932. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.

Inclusion Criteria

Body Mass Index (BMI) must be ≥ 18.0 to ≤ 32.0 kg/m^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.

My overall health is good based on recent medical exams.

Exclusion Criteria

I don't have any serious health issues apart from my current condition.

History of any clinically significant sensitivity or allergy to any medication or food.

I have a history of epilepsy.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive a single dose of ABBV-932 under fasting or fed conditions

1 day

1 visit (in-person)

Pharmacokinetic Assessment

Assessment of the relative bioavailability and effect of food on pharmacokinetics of ABBV-932

6 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

180 days

Treatment Details

Interventions

• ABBV-932

Trial Overview The study is testing ABBV-932, an oral medication. It aims to understand how the body absorbs it (bioavailability) and how food affects its absorption (pharmacokinetics).

Participant Groups

Group I: ABBV-932: Arm E Experimental Treatment 1 Intervention

Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal.

Group II: ABBV-932: Arm D Experimental Treatment 1 Intervention

Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal.

Group III: ABBV-932: Arm C Experimental Treatment 1 Intervention

Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions.

Group IV: ABBV-932: Arm B Experimental Treatment 1 Intervention

Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions.

Group V: ABBV-932: Arm A Experimental Treatment 1 Intervention

Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions.

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois